These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 24626432)

  • 1. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.
    Pendergraft WF; Cortazar FB; Wenger J; Murphy AP; Rhee EP; Laliberte KA; Niles JL
    Clin J Am Soc Nephrol; 2014 Apr; 9(4):736-44. PubMed ID: 24626432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Rhee EP; Laliberte KA; Niles JL
    Clin J Am Soc Nephrol; 2010 Aug; 5(8):1394-400. PubMed ID: 20498238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.
    Bunch DO; McGregor JG; Khandoobhai NB; Aybar LT; Burkart ME; Hu Y; Hogan SL; Poulton CJ; Berg EA; Falk RJ; Nachman PH
    Clin J Am Soc Nephrol; 2013 Mar; 8(3):382-91. PubMed ID: 23293123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
    Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
    Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
    Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
    Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of remission-induction regimens for ANCA-associated vasculitis.
    Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Viviano L; Tchao NK; Phippard DJ; Asare AL; Lim N; Ikle D; Jepson B; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Mueller M; Sejismundo LP; Mieras K; Stone JH;
    N Engl J Med; 2013 Aug; 369(5):417-27. PubMed ID: 23902481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
    N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial.
    Zonozi R; Cortazar FB; Jeyabalan A; Sauvage G; Nithagon P; Huizenga NR; Rosenthal JM; Sipilief A; Cosgrove K; Laliberte KA; Rhee EP; Pendergraft WF; Niles JL
    Ann Rheum Dis; 2024 Feb; 83(3):351-359. PubMed ID: 38123922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
    Pullerits R; Ljevak M; Vikgren J; Bokarewa M
    Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.
    Gopaluni S; Smith RM; Lewin M; McAlear CA; Mynard K; Jones RB; Specks U; Merkel PA; Jayne DR;
    Trials; 2017 Mar; 18(1):112. PubMed ID: 28270229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
    Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
    Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
    Roccatello D; Vangelista A; Pani A
    G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.
    Jones RB; Ferraro AJ; Chaudhry AN; Brogan P; Salama AD; Smith KG; Savage CO; Jayne DR
    Arthritis Rheum; 2009 Jul; 60(7):2156-68. PubMed ID: 19565480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
    Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
    Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
    Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
    Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
    N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab treatment for vasculitis.
    Jayne D
    Clin J Am Soc Nephrol; 2010 Aug; 5(8):1359-62. PubMed ID: 20671223
    [No Abstract]   [Full Text] [Related]  

  • 19. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
    Kallenberg CG
    Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
    Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
    Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.